Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]
Sana Biotechnology, Inc. (SANA)
Company Research
Source: Yahoo! Finance
Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in the ongoing VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report initial clinical data in 2024 Expect initial clinical data in 1H2024 for investigator-sponsored trial with hypoimmune-modified primary islet cells Completed financing of $189.8 million in gross proceeds to support activities through multiple data readouts Cash position of $311.1 million and expected 2024 operating cash burn below $200 million SEATTLE, May 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the first quarter 2024. “We have four ongoing clinica
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth? [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Sana Biotechnology Reports First Quarter 2024 Financial Results and Business UpdatesGlobeNewswire
- Sana Biotechnology to Present at May and June 2024 Investor ConferencesGlobeNewswire
- Xcell Biosciences Announces New Scientific and Business Advisory Board [Yahoo! Finance]Yahoo! Finance
SANA
Earnings
- 5/8/24 - Miss
SANA
Sec Filings
- 5/8/24 - Form S-8
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- SANA's page on the SEC website